NEW PYRIDOBENZODIAZEPINE DERIVATIVES AS POTENTIAL ANTIPSYCHOTICS - SYNTHESIS AND NEUROCHEMICAL STUDY

被引:56
作者
LIEGEOIS, JFF
BRUHWYLER, J
DAMAS, J
NGUYEN, TP
CHLEIDE, EMG
MERCIER, MGA
ROGISTER, FA
DELARGE, JE
机构
[1] UNIV NAMUR,DEPT EXPTL PSYCHOL,B-5000 NAMUR,BELGIUM
[2] UNIV LIEGE,PHYSIOL LAB,B-4020 LIEGE,BELGIUM
关键词
D O I
10.1021/jm00067a009
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The discovery of a new, safe, atypical antipsychotic remains an important challenge. To achieve this goal, a series of N-methylpiperazinopyrido[2,3-b][1,4]- and -[1,5]- and -pyrido[4,3-b][1,4]- and -[1,5]-benzodiazepines were synthesized. The dopaminergic (D1, D2), serotonergic (5-HT2), and cholinergic (M) affinities, frequently remarked in the action mechanisms of antipsychotic drugs, were determined using their respective in vitro receptor binding assays. All affinities were reduced for each compound. Optimal substituents were found to be in the 2- or 8-position for the retention of affinities, while substitution at the 5-position by acyl or alkyl groups dramatically diminished binding affinities. Pyridobenzodiazepine derivatives, such as clozapine, were found to be inactive or only weakly effective against apomorphine-mediated stereotypes in rats. In an original and complex behavioral model developed in dogs and successfully used to differentiate distinct classes of psychotropic drugs and to discriminate between typical and atypical neuroleptic drugs, 8-chloro-6-(4-methyl-1-piperazinyl)-11H-pyrido[2,3-b][1,4]benzodiazepine (9), 8-methyl-6-(4-methyl-1-piperazinyl)-11H-pyrido[2,3-b][1,4]benzodiazepine (12), and 5-(4-methyl-1-piper-azinyl)-11H-pyrido[2,3-b][1,5]benzodiazepine (16) showed most of the behavioral characteristics previously described for neuroleptics. Their neurochemical profiles, particularly their 5-HT2/D2 pK(i) ratios, were compatible with an atypical antipsychotic effect. These compounds were selected for further investigation. The proposed modulations could lead to new possibilities for the pharmacochemistry of diarylazepines.
引用
收藏
页码:2107 / 2114
页数:8
相关论文
共 70 条
[11]  
BRUHWYLER J, 1992, BEHAV PHARMACOL, V3, P567
[12]  
BURKI HR, 1977, ARZNEIMITTEL-FORSCH, V27-2, P1561
[13]   BINDING OF TYPICAL AND ATYPICAL ANTIPSYCHOTICS TO 5-HT1C AND 5-HT2 SITES - CLOZAPINE POTENTLY INTERACTS WITH 5-HT1C SITES [J].
CANTON, H ;
VERRIELE, L ;
COLPAERT, FC .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 191 (01) :93-96
[14]   HETEROARENOBENZODIAZEPINES .7. SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF A SERIES OF 4-PIPERAZINYLPYRAZOLO[3,4-B]BENZODIAZEPINES AND 4-PIPERAZINYLPYRAZOLO[4,3-B][1,5]BENZODIAZEPINES AS POTENTIAL ANXIOLYTICS [J].
CHAKRABARTI, JK ;
HOTTEN, TM ;
PULLAR, IA ;
TYE, NC .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (12) :2573-2582
[15]   HETEROARENOBENZODIAZEPINES .6. SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF CNS ACTIVITIES OF [1,2,3]TRIAZOLO[4,5-B][1,5]BENZODIAZEPINES, IMIDAZOLO[4,5-B][1,5]BENZODIAZEPINES, AND PYRIDO[2,3-B][1,5]BENZODIAZEPINES - 10-PIPERAZINYL-4H-1,2,3-TRIAZOLO[4,5-B][1,5]BENZODIAZEPINES NEUROLEPTIC ACTIVITY [J].
CHAKRABARTI, JK ;
HOTTEN, TM ;
PULLAR, IA ;
STEGGLES, DJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (10) :2375-2381
[16]   EFFECTS OF CONFORMATIONALLY RESTRICTED 4-PIPERAZINYL-10H-THIENOBENZODIAZEPINE NEUROLEPTICS ON CENTRAL DOPAMINERGIC AND CHOLINERGIC SYSTEMS [J].
CHAKRABARTI, JK ;
HOTTEN, TM ;
MORGAN, SE ;
PULLAR, IA ;
RACKHAM, DM ;
RISIUS, FC ;
WEDLEY, S ;
CHANEY, MO ;
JONES, ND .
JOURNAL OF MEDICINAL CHEMISTRY, 1982, 25 (10) :1133-1140
[17]   HETEROARENOBENZODIAZEPINES .3. 4-PIPERAZINYL-10H-THIENO[2,3-B][1,5]BENZODIAZEPINES AS POTENTIAL NEUROLEPTICS [J].
CHAKRABARTI, JK ;
HORSMAN, L ;
HOTTEN, TM ;
PULLAR, IA ;
TUPPER, DE ;
WRIGHT, FC .
JOURNAL OF MEDICINAL CHEMISTRY, 1980, 23 (08) :878-884
[18]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[19]   AMITRIPTYLINE IN CLOZAPINE-INDUCED SIALORRHOEA [J].
COPP, PJ ;
LAMENT, R ;
TENNENT, TG .
BRITISH JOURNAL OF PSYCHIATRY, 1991, 159 :166-166
[20]   CLOZAPINE ANTAGONISM OF D-1 AND D-2 DOPAMINE RECEPTOR-MEDIATED BEHAVIORS [J].
CRISWELL, HE ;
MUELLER, RA ;
BREESE, GA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 159 (02) :141-147